越来越多的肝动脉灌注(HAI)项目在全球范围内得到建立。迄今为止，关于这种复杂治疗的实践模式在这些项目之间尚未有报道。此项调查旨在识别HAI治疗的当前实践模式，从而在长期目标中明确最佳实践和进行前瞻性研究。使用SurveyMonkeyTM，由12位HAI联盟研究网络（HCRN）外科肿瘤学家开发了一个包含28个问题、评估HAI当前实践的调查问卷。使用内容分析对文本回答进行编码，并计算各类别的频率。根据回答选择的平均排序计算出排名问题的分数。36位（72％）HCRN成员对该调查进行了回应。新项目中HAI最常见的预期初始适应症是不可切除的结直肠肝转移（uCRLM; 100％）和不可切除的肝内胆管癌（uIHC; 56％）。实践模式的演变使得不可切除的结直肠肝转移（uCRLM; 94％）和结直肠肝转移的辅助治疗（adjCRLM; 72％）成为已建立的中心中最常见的HAI指征。对于泵置入的转诊模式在不可切除的结直肠肝转移和不可切除的肝内胆管癌之间有所不同，大部分患者在接受第二线和第一线治疗时被转诊，外科医生更倾向于在结直肠肝转移的一线治疗期间评估患者的HAI治疗效果。考虑到肝外疾病的担忧被评为在考虑患者进行HAI时最重要的因素。HAI治疗的适应症和患者选择因素在大多数HCRN中心相对统一。HCRN中心中辅助HAI治疗的使用增加以及实践模式的整体一致性为前瞻性数据收集和随机临床试验提供了有力的环境。© 2023.外科肿瘤学学会。

An increasing number of hepatic artery infusion (HAI) programs have been established worldwide. Practice patterns for this complex therapy across these programs have not been reported. This survey aimed to identify current practice patterns in HAI therapy with the long-term goal of defining best practices and performing prospective studies.Using SurveyMonkeyTM, a 28-question survey assessing current practices in HAI was developed by 12 HAI Consortium Research Network (HCRN) surgical oncologists. Content analysis was used to code textual responses, and the frequency of categories was calculated. Scores for rank-order questions were generated by calculating average ranking for each answer choice.Thirty-six (72%) HCRN members responded to the survey. The most common intended initial indications for HAI at new programs were unresectable colorectal liver metastases (uCRLM; 100%) and unresectable intrahepatic cholangiocarcinoma (uIHC; 56%). Practice patterns evolved such that uCRLM (94%) and adjuvant therapy for CRLM (adjCRLM; 72%) have become the most common current indications for HAI at established centers. Referral patterns for pump placement differed between uCRLM and uIHC, with most patients referred while receiving second- and first-line therapy, respectively, with physicians preferring to evaluate patients for HAI while receiving first-line therapy for CRLM. Concern for extrahepatic disease was ranked as the most important factor when considering a patient for HAI.Indication and patient selection factors for HAI therapy are relatively uniform across most HCRN centers. The increasing use of adjuvant HAI therapy and overall consistency of practice patterns among HCRN centers provides a robust environment for prospective data collection and randomized clinical trials.© 2023. Society of Surgical Oncology.